Liver transplantation for malignancy: Current treatment strategies and future perspectives

Table 2 Liver transplantation for hepatic epithelioid hemangioendothelioma

Database	Author	Year	Year of LT	n	Age of patients	Female	Mean fullow-up	Overall survival in %			DFS in %			LDLT	Extrahep.	Recurrence
								1 yr	3 yr	5 yr	1 yr	3 yr	5 yr
Mayo	Grotz	2010	1984-2007	11	21-79 yr (mean 46.7 yr)	77%	42 mo	91	73	73	64	46	46	NR	18%	NR
UNOS	Rodriguez	2008	1987-2005	110	0-70 yr (median 36 yr)	68%	24 mo	80	68	64	NR	NR	NR	n.t.	NR	NR
Canada	Nudo	2008	1991-2005	11	18-52 yr (mean 38.7 yr)	77%	81 mo	82	82	calc 82	80	69	69	0%	36%	45%
Europe	Lerut	2007	1989-2004	59	4-65 yr (median 41 yr)	57%	79 mo	93	NR	83	90	NR	82	5%	17%	24%
Review	Mehrabi	2006	1984-2006	128	mean 41.7 yr	58%	NR	96	77	54	NR	NR	NR	2%	NR	NR
Pittsburgh	Madariaga	1995	1976-1993	17	28-58	53%	56 mo	100	86	67	88	68	59	NR	NR	NR
Review	Yokoyama	1990	1980-1988	8	NR	NR	25 mo	88	73	48	NR	NR	NR	NR	NR	50%
Pittsburgh	Marino	1988	1963-1987	10	24-52.5 yr (median 29.5 yr)	60%	NR	NR	NR	calc 76	NR	NR	NR	NR	50%	30%

LT: Liver transplantation; NR: Not reported; DFS: Disease-free survival; LDLT: Living-donor liver transplantation; UNOS: United Network for Organ Sharing.